目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 MARKET ESTIMATION
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 TOP-DOWN APPROACH
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 PROTEIN EXPRESSION MARKET OVERVIEW
4.2 NORTH AMERICA: PROTEIN EXPRESSION MARKET, BY OFFERING AND COUNTRY, 2023
4.3 PROTEIN EXPRESSION MARKET SHARE, BY SYSTEM TYPE, 2024 VS. 2029
4.4 PROTEIN EXPRESSION PRODUCTS MARKET, BY END USER, 2023
4.5 PROTEIN EXPRESSION SERVICES MARKET, BY END USER, 2023
4.6 PROTEIN EXPRESSION MARKET, BY COUNTRY

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing demand for biologics
5.2.1.2 Rise in R&D in pharmaceutical and biopharmaceutical industries
5.2.1.3 Growing use of artificial intelligence and machine learning
5.2.1.4 Increasing shift toward personalized medicines
5.2.1.5 Growing outsourcing of clinical activities
5.2.2 RESTRAINTS
5.2.2.1 High cost of protein expression offerings
5.2.2.2 Renewed focus on small molecules in drug development
5.2.3 OPPORTUNITIES
5.2.3.1 Growing emphasis on plant-based and cell-free expression systems
5.2.3.2 Booming market in emerging economies
5.2.3.3 Increasing development of synthetic protein production technologies
5.2.3.4 Growing use of recombinant proteins
5.2.4 CHALLENGES
5.2.4.1 Production cost and efficiency issues
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF PROTEIN EXPRESSION PRODUCTS
5.4.2 AVERAGE SELLING PRICE, BY KEY PLAYER
5.4.2.1 Average selling price of system types, by key player
5.4.2.2 Average selling price trend of protein expression instruments, by key player
5.4.3 AVERAGE SELLING PRICE, BY REGION
5.4.3.1 Average selling price of protein expression consumable products, by region
5.4.3.2 Average selling price trend of protein expression instruments, by region
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT/FUNDING ACTIVITY
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Recombinant DNA technology
5.9.1.2 Transfection technologies
5.9.1.2.1 Reagent-based transfection
5.9.1.2.2 Instrument-based transfection
5.9.1.2.3 Virus-based transfection
5.9.1.3 Protein expression systems
5.9.1.3.1 Bacterial expression systems
5.9.1.3.2 Mammalian expression systems
5.9.1.3.3 Yeast expression systems
5.9.1.3.4 Insect expression systems
5.9.1.3.5 Cell-free expression systems
5.9.2 ADJACENT TECHNOLOGIES
5.9.2.1 Extraction technologies
5.9.2.1.1 Non-mechanical methods
5.9.2.1.2 Mechanical methods
5.9.2.2 Purification and characterization technologies
5.9.2.2.1 Protein purification technologies
5.9.2.2.2 Protein characterization technologies
5.9.3 COMPLEMENTARY TECHNOLOGIES
5.9.3.1 High-throughput technologies
5.9.3.2 Computation protein designing
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA
5.11.2 EXPORT DATA
5.12 KEY CONFERENCES AND EVENTS, 2024-2025
5.13 REGULATORY ANALYSIS
5.13.1 REGULATORY LANDSCAPE
5.13.1.1 North America
5.13.1.2 Europe
5.13.1.3 Emerging economies
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14 PORTER'S FIVE FORCES ANALYSIS
5.14.1 INTENSITY OF COMPETITIVE RIVALRY
5.14.2 BARGAINING POWER OF SUPPLIERS
5.14.3 BARGAINING POWER OF BUYERS
5.14.4 THREAT OF NEW ENTRANTS
5.14.5 THREAT OF SUBSTITUTES
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 BUYING CRITERIA
5.15.2.1 Buying criteria for protein expression products
5.15.2.2 Buying criteria for protein expression services
5.16 IMPACT OF AI/GEN AI ON PROTEIN EXPRESSION MARKET
5.16.1 INTRODUCTION
5.16.2 MARKET POTENTIAL FOR PROTEIN EXPRESSION APPLICATIONS
5.16.3 AI USE CASES
5.16.4 KEY COMPANIES IMPLEMENTING AI
5.16.5 FUTURE OF GENERATIVE AI IN PROTEIN EXPRESSION ECOSYSTEM

6 PROTEIN EXPRESSION MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCTS
6.2.1 REAGENTS & KITS
6.2.1.1 Increasing use for cloning, transfection, purification, and characterization to spur growth
6.2.2 EXPRESSION VECTORS
6.2.2.1 Growing production of complex proteins to propel market
6.2.3 COMPETENT CELLS
6.2.3.1 Increasing demand for therapeutic proteins to expedite growth
6.2.4 INSTRUMENTS & SOFTWARE
6.2.4.1 Increasing demand for biopharmaceuticals and personalized therapies to augment growth
6.3 SERVICES
6.3.1 GROWING UTILIZATION OF PROTEIN EXPRESSION SERVICES FOR LARGE-SCALE PRODUCTION TO FUEL MARKET

7 PROTEIN EXPRESSION MARKET, BY SYSTEM TYPE
7.1 INTRODUCTION
7.2 MAMMALIAN CELL EXPRESSION SYSTEMS
7.2.1 CHINESE HAMSTER OVARY (CHO) CELL SYSTEMS
7.2.1.1 High viability, rapid growth, and improved expression levels to support growth
7.2.2 HUMAN EMBRYONIC KIDNEY (HEK 293) CELL SYSTEMS
7.2.2.1 Wide usage in transient transfection studies to augment growth
7.2.3 OTHER MAMMALIAN CELL SYSTEMS
7.3 PROKARYOTIC EXPRESSION SYSTEMS
7.3.1 ESCHERICHIA COLI SYSTEMS
7.3.1.1 High cell density and low cost of media to stimulate growth
7.3.2 OTHER PROKARYOTIC EXPRESSION SYSTEMS
7.4 INSECT CELL EXPRESSION SYSTEMS
7.4.1 BACULOVIRUS SYSTEMS
7.4.1.1 Increasing production of biologically active and functional recombinant proteins to speed up growth
7.4.2 OTHER INSECT CELL EXPRESSION SYSTEMS
7.5 YEAST EXPRESSION SYSTEMS
7.5.1 PICHIA SYSTEMS
7.5.1.1 Rising production of antibody fragments, and vaccines to fuel growth
7.5.2 SACCHAROMYCES SYSTEMS
7.5.2.1 Increasing use of saccharomyces systems for producing heterologous proteins to accelerate growth
7.5.3 OTHER YEAST EXPRESSION SYSTEMS
7.6 CELL-FREE EXPRESSION SYSTEMS
7.6.1 INCREASING DEMAND FOR RECOMBINANT PROTEINS TO SUPPORT MARKET
7.7 ALGAL-BASED EXPRESSION SYSTEMS
7.7.1 GROWING USE OF ALGAL-BASED EXPRESSION SYSTEMS IN ANTIBODY AND VACCINE GENERATION TO BOOST MARKET

8 PROTEIN EXPRESSION MARKET, BY WORKFLOW
8.1 INTRODUCTION
8.2 CLONING & TRANSFECTION
8.2.1 CONTINUOUS REPLENISHMENT OF CONSUMABLES AND REAGENTS TO SUPPORT MARKET
8.3 TRANSCRIPTION, TRANSLATION, AND POST-TRANSLATIONAL MODIFICATION (PTM)
8.3.1 GROWING NEED FOR FUNCTIONAL AND STABLE PROTEINS TO DRIVE MARKET
8.4 EXTRACTION, PURIFICATION, AND CHARACTERIZATION
8.4.1 NEED TO ADHERE TO REQUIRED STANDARDS FOR SUITABLE APPLICATIONS TO DRIVE MARKET

9 PROTEIN EXPRESSION MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 THERAPEUTIC APPLICATIONS
9.2.1 RISING DEMAND FOR BIOLOGICS THERAPIES TO FACILITATE GROWTH
9.3 RESEARCH APPLICATIONS
9.3.1 GROWING INTEREST IN PROTEOMICS, GENOMICS, AND DRUG DISCOVERY TO BOOST MARKET
9.4 INDUSTRIAL APPLICATIONS
9.4.1 INCREASING USE OF PROTEINS IN COSMETICS, TEXTILES, AND INDUSTRIAL ENZYMES TO PROMOTE GROWTH

10 PROTEIN EXPRESSION PRODUCTS MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 INCREASING APPROVALS FOR BIOLOGICS TO STIMULATE GROWTH
10.3 ACADEMIC & RESEARCH INSTITUTES
10.3.1 RISE IN GOVERNMENT AND PRIVATE FUNDING TO CONTRIBUTE TO MARKET GROWTH
10.4 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS & CDMOS)
10.4.1 INCREASING OUTSOURCING AND COLLABORATIONS FOR PHARMACEUTICAL MANUFACTURING AND CLINICAL TRIALS TO SUSTAIN MARKET
10.5 OTHER END USERS

11 PROTEIN EXPRESSION SERVICES MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.2.1 INCREASING SHIFT TOWARD DRUG DEVELOPMENT OUTSOURCING TO FAVOR GROWTH
11.3 ACADEMIC & RESEARCH INSTITUTES
11.3.1 RISING PARTNERSHIPS BETWEEN ACADEMIA AND CONTRACT RESEARCH ORGANIZATIONS TO AID GROWTH
11.4 OTHER END USERS

12 PROTEIN EXPRESSION MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 Growing focus on developing new therapeutics and protein-based drugs to drive market
12.2.3 CANADA
12.2.3.1 Increasing incidence of cancer and prevalence of public-private partnerships to sustain growth
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 Increasing proteomics-based research and healthcare investments to promote growth
12.3.3 UK
12.3.3.1 Growing development of immunotherapies, vaccines, and proteomics to fuel market
12.3.4 FRANCE
12.3.4.1 Rise in funding for proteomics and genomics to spur growth
12.3.5 ITALY
12.3.5.1 Growing life science research supported by universities and research institutions to boost market
12.3.6 SPAIN
12.3.6.1 Increasing international collaborations for drug development to fuel market
12.3.7 NETHERLANDS
12.3.7.1 Presence of advanced infrastructure to fuel market
12.3.8 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Extensive government funding in genomics and protein research to boost market
12.4.3 JAPAN
12.4.3.1 Increasing initiatives by government associations in life sciences sector to support market growth
12.4.4 INDIA
12.4.4.1 Rising collaborations between private sector and academia to facilitate growth
12.4.5 AUSTRALIA
12.4.5.1 Growing focus on developing new proteins and peptides to drive market
12.4.6 SOUTH KOREA
12.4.6.1 Increasing research & development of novel therapies to facilitate growth
12.4.7 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Growing industrial investments to propel market
12.5.3 MEXICO
12.5.3.1 Increase in chronic diseases and robust research ecosystem to expedite growth
12.5.4 ARGENTINA
12.5.4.1 Rise in biotechnology and pharmaceutical research & development to augment growth
12.5.5 REST OF LATIN AMERICA
12.6 MIDDLE EAST
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
12.6.2 GCC COUNTRIES
12.6.2.1 Strategic investments between government authorities and private players to drive market
12.6.3 REST OF MIDDLE EAST
12.7 AFRICA
12.7.1 FAVORABLE INSURANCE PROGRAMS AND CLINICAL TRIALS TO CONTRIBUTE TO MARKET GROWTH
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2021-2024
13.3 REVENUE ANALYSIS, 2021-2023
13.4 MARKET SHARE ANALYSIS, 2023
13.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2023
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
13.5.5.1 Company footprint
13.5.5.2 Region footprint
13.5.5.3 Offering footprint
13.5.5.4 Expression system footprint
13.5.5.5 Application footprint
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
13.6.5.1 Detailed list of key startups/SMES
13.6.5.2 Competitive benchmarking of startups/SMEs
13.7 COMPANY VALUATION AND FINANCIAL METRICS
13.7.1 COMPANY VALUATION
13.7.2 FINANCIAL METRICS
13.8 BRAND/PRODUCT COMPARISON
13.9 COMPETITIVE SCENARIO
13.9.1 PRODUCT/SERVICE LAUNCHES
13.9.2 DEALS
13.9.3 EXPANSIONS

14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 THERMO FISHER SCIENTIFIC INC.
14.1.1.1 Business overview
14.1.1.2 Products and services offered
14.1.1.3 Recent developments
14.1.1.3.1 Product/Service launches
14.1.1.3.2 Deals
14.1.1.3.3 Expansions
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 MERCK KGAA
14.1.2.1 Business overview
14.1.2.2 Products and services offered
14.1.2.3 Recent developments
14.1.2.3.1 Deals
14.1.2.3.2 Expansions
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 DANAHER CORPORATION
14.1.3.1 Business overview
14.1.3.2 Products and services offered
14.1.3.3 Recent developments
14.1.3.3.1 Product/Service launches
14.1.3.3.2 Deals
14.1.3.3.3 Expansions
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses and competitive threats
14.1.4 AGILENT TECHNOLOGIES, INC.
14.1.4.1 Business overview
14.1.4.2 Products and services offered
14.1.4.3 MnM view
14.1.4.3.1 Key strengths
14.1.4.3.2 Strategic choices
14.1.4.3.3 Weaknesses and competitive threats
14.1.5 SARTORIUS AG
14.1.5.1 Business overview
14.1.5.2 Products and services offered
14.1.5.3 Recent developments
14.1.5.3.1 Deals
14.1.5.3.2 Expansions
14.1.5.4 MnM view
14.1.5.4.1 Key strength
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses and competitive threats
14.1.6 GENSCRIPT
14.1.6.1 Business overview
14.1.6.2 Products and services offered
14.1.6.3 Recent developments
14.1.6.3.1 Product/Service launches
14.1.6.4 MnM view
14.1.6.4.1 Key strengths
14.1.6.4.2 Strategic choices
14.1.6.4.3 Weaknesses and competitive threats
14.1.7 TAKARA BIO INC.
14.1.7.1 Business overview
14.1.7.2 Products and services offered
14.1.8 BIO-RAD LABORATORIES, INC.
14.1.8.1 Business overview
14.1.8.2 Products and services offered
14.1.9 QIAGEN
14.1.9.1 Business overview
14.1.9.2 Products and services offered
14.1.10 CHARLES RIVER LABORATORIES
14.1.10.1 Business overview
14.1.10.2 Products and services offered
14.1.11 CORNING INCORPORATED
14.1.11.1 Business overview
14.1.11.2 Products and services offered
14.1.12 LONZA
14.1.12.1 Business overview
14.1.12.2 Products and services offered
14.1.12.3 Recent developments
14.1.12.3.1 Product/Service launches
14.1.12.3.2 Deals
14.1.13 FUJIFILM IRVINE SCIENTIFIC, INC.
14.1.13.1 Business overview
14.1.13.2 Products and services offered
14.1.13.3 Recent developments
14.1.13.3.1 Product/Service launches
14.1.13.3.2 Deals
14.1.13.3.3 Expansions
14.1.14 SYNGENE INTERNATIONAL LIMITED
14.1.14.1 Business overview
14.1.14.2 Products and services offered
14.1.14.3 Recent developments
14.1.14.3.1 Product/Service launches
14.1.15 LGC LIMITED
14.1.15.1 Business overview
14.1.15.2 Products and services offered
14.1.16 EUROFINS SCIENTIFIC
14.1.16.1 Business overview
14.1.16.2 Products and services offered
14.1.17 AJINOMOTO CO., INC.
14.1.17.1 Business overview
14.1.17.2 Products and services offered
14.2 OTHER PLAYERS
14.2.1 PROMEGA CORPORATION
14.2.2 SINO BIOLOGICAL, INC.
14.2.3 RAYBIOTECH, INC.
14.2.4 BIONEER CORPORATION
14.2.5 ORIGENE TECHNOLOGIES, INC.
14.2.6 NEW ENGLAND BIOLABS
14.2.7 ACCURUS BIOSCIENCES
14.2.8 ARAGEN LIFE SCIENCES LTD.
14.2.9 OXFORD EXPRESSION TECHNOLOGIES LTD
14.2.10 PROTEOGENIX INC.
14.2.11 ABEOMICS

15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS